A survey of resistance mutations to reverse transcriptase inhibitors (RTIs) among HIV-1 patients in northeast of Iran

Document Type : Original article

Authors

1 Department of Microbiology and Virology, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

2 Immunogenetic and Cell Culture Department, Immunology Research Center, School of Medicine, Mashhad University of Medical Sciences, Mashhad, Iran

3 Hepatitis and AIDS Department, Pasteur Institute of Iran, Tehran, Iran

4 Antimicrobial Resistance Research Center, Mashhad University of Medical Sciences, Mashhad, Iran

Abstract

The use of a combination of three-drug regimen has improved HIV-1 infected patients' life span and quality; however the emergence of drug-resistant strains remains a main problem. Reverse transcriptase inhibitors (RTIs) consist of a main part of highly active anti-retroviral therapy (HAART) regimen. The present study aimed to investigate resistant mutations to RTI drugs in both treatment naïve and under treatment HIV patients in Mashhad city, north-eastern Iran. RNA was extracted from sera of 22 treatment naïve and 22 under treatment patients. The mean age of under treated and treatment naive groups were 38.5±6.7 and 40.8±7.9 respectively. cDNA was synthesized and amplified with Nested PCR assay targeting specific sequences of RT gene. The PCR products were sent for sequencing. Bidirectional sequencing results were analysed using HIV drug resistance database supplied by Stanford University (HIV Drug Resistance Database, https://hivdb.stanford.edu). Among under treatment patients 10 out of 22 (45%) had at least one high-level resistance mutation which was higher than high level resistance mutation rate among treatment naive cases (P<0.01). Detected resistance mutations were as follows: K101E, K103N, K103E, V106M, V108I, E138A, V179T, Y181C, M184V, Y188L, Y188H, Y188F, G190A, L210W, T215F, T215Y, K219Q, and P225H. A high level of resistance mutations to RT inhibitors was observed that causes drug resistance especially against lamivudine (3TC). Such mutations should be considered as probable responsible for therapeutic failure. Serial surveillance studies of circulating drug resistance mutations are recommended.

Keywords

References

  1. Haider MR, Gao D, Zou Z, Dong B, Zhang W, Chen T, Cui W, Ma Y. Secular trends in HIV/AIDS mortality in China from 1990 to 2016: Gender disparities. PLos One 2019;14:e0219689.
  2. Haghdoost AA, Mostafavi, E, Mirzadeh A, Navadeh S. Modeling of HIV/AIDS in Iran up to 2014. J AIDS HIV Res 2011;3:231-239.
  3. Gharagozloo M, Doroudchi M, Farjadian S, Pezeshki AM, Ghaderi A. The frequency of CCR5Δ32 and CCR2-64I in southern Iranian normal population. Immunol Lett 2005; 96:277-281.
  4. Perrino T, Gonzalez-Soldevilla A, Pantin H, Szapocznik J. The role of families in adolescent HIV prevention: A review. Clin Child Fam Psychol Rev 2000;3:81-96.
  5. Barbaro G, Scozzafava A, Mastrolorenzo A, Supuran CT. Highly active antiretroviral therapy: current state of the art, new agents and their pharmacological interactions useful for improving therapeutic outcome. Curr Pharm Des 2005;11:1805-1843.
  6. Margolis AM, Heverling H, Pham PA, Stolbach A. A review of the toxicity of HIV medications. J Med Toxicol 2014;10:26-39.
  7. Hamers RL, de Wit TFR, Holmes CB. HIV drug resistance in low-income and middle-income countries. Lancet HIV 2018;5:e588-e596.
  8. Rojas Sánchez P, Holguín A. Drug resistance in the HIV-1-infected paediatric population worldwide: a systematic review. J Antimicrob Chemother 2014;69:2032-2042.
  9. Sluis-Cremer N, Arion D, Parniak M. Molecular mechanisms of HIV-1 resistance to nucleoside reverse transcriptase inhibitors (NRTIs). Cell Mol Life Sci 2000;57:1408-1422.
  10. Holec AD, Mandal S, Prathipati PK, Destache CJ. Nucleotide reverse transcriptase inhibitors: a thorough review, present status and future perspective as HIV therapeutics. Curr HIV Res 2017;15:411-421.
  11. de Béthune MP. Non-nucleoside reverse transcriptase inhibitors (NNRTIs), their discovery, development, and use in the treatment of HIV-1 infection: a review of the last 20 years (1989–2009). Antiviral Res 2010;85:75-90.
  12. Zapor MJ, Cozza KL, Wynn GH, Wortmann GW, Armstrong SC. Antiretrovirals, Part II: focus on non-protease inhibitor antiretrovirals (NRTIs, NNRTIs, and fusion inhibitors). Psychosomatics 2004;45:524-235.
  13. Sierra-Aragon S, Walter H. Targets for inhibition of HIV replication: entry, enzyme action, release and maturation. Intervirology 2012;55:84-97.
  14. D’Aquila RT, Schapiro JM, Brun-Vézinet F, Clotet B, Conway B, Demeter LM, Grant RM, Johnson VA, Kuritzkes DR, Loveday C, Shafer RW, Richman DD. Drug resistance mutations in HIV-1. Top HIV Med 2003;11:92-96.
  15. De Clercq E. Anti-HIV drugs: 25 compounds approved within 25 years after the discovery of HIV. Int J Antimicrob Agents 2009;33:307-320.
  16. Weller IV, Williams I. ABC of AIDS. Antiretroviral drugs. BMJ 2001;322:1410-1412.
  17. Sluis-Cremer N, Temiz NA, Bahar I. Conformational changes in HIV-1 reverse transcriptase induced by nonnucleoside reverse transcriptase inhibitor binding. Curr HIV Res 2004;2:323-332.
  18. Mirzaei M, Farhadian M, Poorolajal J, Afasr Kazerooni P, Tayeri K, Mohammadi Y. Life expectancy of HIV-positive patients after diagnosis in Iran from 1986 to 2016: A retrospective cohort study at national and sub-national levels. Epidemiol Health 2018;40:e2018053.
  19. Bagheri Amiri F, Doosti-Irani A, Sedaghat A, Fahimfar N, Mostafavi E. Knowledge, Attitude, and Practices Regarding HIV and TB Among Homeless People in Tehran, Iran. Int J Health Policy Manag 2017;7:549-555.
  20. Secretariat NAC. Islamic Republic of Iran AIDS Progress Report. Ministry of Health and Medical Education Tehran;2015.
  21. Edition T. WHO manual for HIV drug resistance testing using dried blood spot specimens. Geneva: World Health Organization; 2020. Licence: CC BY-NC-SA 3.0 IGO.
  22. Bennett DE, Camacho RJ, Otelea D, Kuritzkes DR, Fleury H, Kiuchi M, Heneine W, Kantor R, Jordan MR, Schapiro JM, Vandamme AM, Sandstrom P, Boucher CAB, Van de Vijver D, Rhee SY, Liu TF, Pillay D, Shafer RW. Drug resistance mutations for surveillance of transmitted HIV-1 drug-resistance: 2009 update. PLoS One 2009;4:e4724.
  23. Shafer RW, Rhee SY, Pillay D, Miller V, Sandstrom P, Schapiro JM, Kuritzkes DR, Bennett D. HIV-1 protease and reverse transcriptase mutations for drug resistance surveillance. AIDS 2007;21:215-223.
  24. Nasiri-Tajabadi Z, Salim FB, Najafzadeh MJ, Kalantari S, Garshasbi S, Jamehdar SA, Farsiani H, Mazaheri Z, Sankian M, Youssefi M. A surveillance on protease inhibitor resistance-associated mutations among Iranian HIV-1 patients. Arch Clin Infect Dis 2018; 13:e69153.
  25. Hu Z, Giguel F, Hatano H, Reid P, Lu J, Kuritzkes DR. Fitness comparison of thymidine analog resistance pathways in human immunodeficiency virus type 1. J Virol 2006;80:7020-7027.
  26. Betancor G, Nevot M, Mendieta J, Gómez-Puertas P, Martínez MA, Menéndez-Arias L. Molecular basis of the association of H208Y and thymidine analogue resistance mutations M41L, L210W and T215Y in the HIV-1 reverse transcriptase of treated patients. Antiviral Res 2014;106:42-52.
  27. Clavel F, Hance AJ. HIV drug resistance. N Engl J Med 2004;350:1023-1035.
  28. Johnson VA, Calvez V, Günthard HF, Paredes R, Pillay D, Shafer RW, Wensing AM, Richman DD. Update of the drug resistance mutations in HIV-1: March 2013. Top Antivir Med 2013;21:6-7.
  29. Ibe S, Sugiura W. Clinical significance of HIV reverse-transcriptase inhibitor-resistance mutations. Future Microbiol 2011;6:295-315.
  30. von Wyl V, Yerly S, Böni J, Shah C, Cellerai C, Klimkait T, Battegay M, Bernasconi E, Cavassini M, Furrer H, Hirschel B, Vernazza PL, Ledergerber B, Gunthard HF, Swiss HIV Cohort Study. Incidence of HIV-1 Drug Resistance Among Antiretroviral Treatment–Naive Individuals Starting Modern Therapy Combinations. Clin Infect Dis 2012;54:131-140.
  31. Molina JM, Cahn P, Grinsztejn B, Lazzarin A, Mills A, Saag M, Supparatpinyo K, Walmsley S, Crauwels H, Rimsky LT, Vanveggel S, Boven K, ECHO study group. Rilpivirine versus efavirenz with tenofovir and emtricitabine in treatment-naive adults infected with HIV-1 (ECHO): a phase 3 randomised double-blind active-controlled trial. Lancet 2011;378:238-246.
  32. Hachiya A, Kodama EN, Sarafianos SG, Schuckmann MM, Sakagami Y, Matsuoka M, Takiguchi M, Gatanaga H, Oka S. Amino acid mutation N348I in the connection subdomain of human immunodeficiency virus type 1 reverse transcriptase confers multiclass resistance to nucleoside and nonnucleoside reverse transcriptase inhibitors. J Virol 2008;82:3261-3270.
  33. Hu Z, Kuritzkes DR. Interaction of reverse transcriptase (RT) mutations conferring resistance to lamivudine and etravirine: effects on fitness and RT activity of human immunodeficiency virus type 1. J Virol 2011;85:11309-11314.
  34. Abdissa A, Yilma D, Fonager J, Audelin AM, Christensen LH, Olsen MF, Tesfaye M, Kaestel P, Girma T, Aseffa A, Friis H, Pedersen C, Andersen AB. Drug resistance in HIV patients with virological failure or slow virological response to antiretroviral therapy in Ethiopia. BMC Infect Dis 2014;14:181.
  35. Gong J, Wang XQ, Tong X, Shen XH, Yang RG. Emerging trends of drug-resistant HIV-1 among drug-treated patients in former blood donors in Hubei, China: a three-year surveillance from 2004 to 2006. Virol Sin 2011;26:386-392.
  36. Hajabdulbaghy M, Soodbakhsh A, Soleimani A. The prevalence of drug resistance in patients with HIV/AIDS attending to Imam Khomeini Hospital in Tehran, Iran during 2008-2009: letter to editor. Tehran University Med J 2011;69:271-272.
  37. Naziri H, Tabarraei A, Ghaemi A, Davarpanah MA, Javid N, Moradi A. Drug-Resistance-Associated Mutations and HIV Sub-Type Determination in Drug-Naïve and HIV-Positive Patients under Treatment with Antiretroviral Drugs. Med Lab J 2013;7:1-8.
  38. Baesi K, Ravanshad M, Hosseini Y, Haji Abdolbaghi M. Drug resistance profile and subtyping of HIV-1 RT gene among Iranian under-treatment patients. Iran J Biotechnol 2012;10:1-7.
  39. Yap SH, Sheen CW, Fahey J, Zanin M, Tyssen D, Lima VD, Wynhoven B, Kuiper M, Sluis-Cremer N, Harrigan PR, Tachedjian G. N348I in the connection domain of HIV-1 reverse transcriptase confers zidovudine and nevirapine resistance. PLoS Med 2007;4:e335.
  40. Xu HT, Oliveira M, Quashie PK, McCallum M, Han Y, Quan Y, Brenner BG, Wainberg MA. Subunit-selective mutational analysis and tissue culture evaluations of the interactions of the E138K and M184I mutations in HIV-1 reverse transcriptase. J Virol 2012;86:8422-8431.
  41. Johnson VA, Brun-Vézinet F, Clotet B, Gunthard HF, Kuritzkes DR, Pillay D, Schapiro JM, Richman DD. Update of the drug resistance mutations in HIV-1: 2007. Top HIV Med 2007;15:119-125.
  42. Baesi K, Ravanshad M, Ghanbarisafari M, Saberfar E, Seyedalinaghi S, Volk JE. Antiretroviral drug resistance among antiretroviral‐naïve and treatment experienced patients infected with HIV in Iran. J Med Virol 2014;86:1093-1098.
  43. Naziri H, Baesi K, Moradi A, Aghasadeghi MR, Tabarraei A, McFarland W, Davarpanah MA. Antiretroviral drug resistance mutations in naïve and experienced patients in Shiraz, Iran, 2014. Arch Virol 2016;161:2503-2509.

Files

Share

How to cite

Statistics